Last reviewed · How we verify

QRxPharma Inc. — Portfolio Competitive Intelligence Brief

QRxPharma Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Oxycodone HCl Oxycodone HCl marketed Opioid analgesic Mu (μ) opioid receptor Pain Management
Q8003 Q8003 phase 3 kappa opioid receptor antagonist kappa opioid receptor Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Ajay Wasan, MD, Msc · 1 shared drug class
  3. Alza Corporation, DE, USA · 1 shared drug class
  4. Archimedes Development Ltd · 1 shared drug class
  5. Asbjørn Mohr Drewes · 1 shared drug class
  6. Astellas Pharma Inc · 1 shared drug class
  7. BioDelivery Sciences International · 1 shared drug class
  8. AdventHealth · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for QRxPharma Inc.:

Cite this brief

Drug Landscape (2026). QRxPharma Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/qrxpharma-inc. Accessed 2026-05-14.

Related